
|Articles|May 15, 2003
ICL effective treatment for moderate, high hyperopia
Author(s)Julia Talsma
San Francisco-At 1-year follow-up, the majority of patients who received the hyperopic Implantable Contact Lens (ICL, STAAR Surgical, Monrovia, CA) for correction of moderate to high hyperopia were satisfied with an uncorrected visual acuity (UCVA) of at least 20/40 or better, noted Paul J. Dougherty, MD, who spoke during the American Society of Cataract and Refractive Surgery Annual Meeting.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Opus Genetics launches phase 1/2 MERTK gene therapy trial
3
FDA approves NDA labeling supplement allowing re-administration of iDose TR
4
FDA Type C meeting supports phase 2b/3 pathway for urcosimod in neuropathic corneal pain
5



























